Introduction
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disorder, having an estimated annual incidence of 0.1% and affecting 2% to 5% of the population during their lifetimes. Approximately 20% of patients with PE will die before diagnosis or on the first day. For those surviving more than 1 day, up to 11% may die in the first 3 months even with adequate therapy, although many of these patients succumb to comorbidities associated with VTE (eg, cancer) rather than from PE itself.1 Long-term complications of VTE include postphlebitic syndrome (after DVT) and chronic thromboembolic pulmonary hypertension (after PE), which develop in up to 40% and 1% to 4% of cases, respectively. Anticoagulant therapy effectively treats symptoms and decreases the risk of recurrent VTE; however, its use increases the risk of major hemorrhage, which may be fatal in up to 25% of cases.2 Given the potential for poor outcomes of patients with VTE and the risks of major hemorrhage associated with anticoagulant therapy, it is key that timely, accurate diagnostic strategies are available to correctly diagnose VTE when present and to safely rule it out when absent. This review provides an overview of the management of suspected VTE, including diagnosis and initial treatment.

Clinical diagnosis
Common symptoms of DVT are unilateral calf or thigh pain, leg swelling, or redness. In general, only 10% to 20% of patients investigated for DVT actually have the disease. In the majority of cases, PE is suspected due to dyspnea and pleuritic chest pain either alone or in combination.3 Patients with massive PE may experience syncope associated with findings of hemodynamic collapse. At the other extreme, patients with PE involving only segmental or subsegmental pulmonary arteries may have minimal or no symptoms.4 Many patients have one or more well-recognized risk factors such as recent surgery or hospitalization, cancer, previous VTE, or obesity.

All patients with clinically suspected VTE should undergo a careful clinical examination considering signs and symptoms of VTE, risk factors for this diagnosis, and whether there are other potential explanations for their symptoms. Although, in isolation, none of the symptoms or signs of VTE are diagnostic, it has been well established that clinical prediction rules incorporating signs, symptoms, and risk factors can be accurately applied to categorize patients as low, moderate, or high probability (Table 1) or “likely” or “unlikely” to have DVT or PE. Once the assessment is complete, if the clinician believes VTE is a diagnostic possibility, he or she should assign a pretest probability of VTE to decide on the best diagnostic strategy. Pretest probability is useful because Bayes theorem indicates that with a reasonably sensitive and specific test, the lower the pretest probability, the more likely a positive test result will be falsely positive, whereas with a high pretest probability, the more likely a negative test result will be falsely negative. Concordant results are likely to be true.5 For DVT, more than 14 studies have demonstrated the reproducibility of the Wells model and, for PE, more than 52 studies and 55,000 patients confirm that the Wells rule or the revised Geneva rule are acceptable for PE, although one study suggested superiority of the Wells rule.6-8 These studies were management studies proving the safety for clinical use, and at least one demonstrated that the Wells rule can be safely used by trainees.9 The PE meta-analysis suggests that a gestalt approach can be used, but these results should be carefully interpreted because clinicians often disagree on the pretest probability of PE using gestalt.10 Experience seems to influence the assessment and gestalt assessment tends to categorize fewer patients into the useful categories of high or low11 when the 3-category classification is used. Furthermore, most studies reporting gestalt estimation were conducted at centers with ample experience in the use of the proven clinical prediction, thereby perhaps overestimating their “gestalt” abilities.
Table 1. Clinical probability scores for PE and DVT

<table>
<thead>
<tr>
<th>Variable</th>
<th>Points</th>
<th>PE: Modified Geneva</th>
<th>PE: Wells</th>
<th>Points</th>
<th>Variable</th>
<th>Points</th>
<th>DVT: Wells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age 65 y or older</td>
<td>1</td>
<td>Signs or symptoms of DVT</td>
<td>3</td>
<td></td>
<td>Active cancer (treatment ongoing or within previous 6 mo or palliative)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Previous DVT or PE</td>
<td>3</td>
<td>Alternative diagnosis is less likely than PE</td>
<td>3</td>
<td></td>
<td>Paralysis, paresis, or recent platter immobilization of the lower extremities</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Surgery or fracture within 1 mo</td>
<td>2</td>
<td>Heart rate &gt; 100 bpm</td>
<td>1.5</td>
<td></td>
<td>Recently bedridden for more than 3 d or major surgery within 4 wk</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Active malignant condition</td>
<td>2</td>
<td>Immortalization/surgery in previous 4 wk</td>
<td>1.5</td>
<td></td>
<td>Localized tenderness along distribution of the deep venous system</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Unilateral lower limb pain</td>
<td>3</td>
<td>Prior history of DVT or PE</td>
<td>1.5</td>
<td></td>
<td>Entire leg swollen</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Pain or deep palpitation of lower limb</td>
<td>4</td>
<td>Hemoptysis</td>
<td>1</td>
<td></td>
<td>Calf swelling by more than 3 cm compared with asymptomatic leg (measured 10 cm below tibial tuberosity)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoptysis</td>
<td>0</td>
<td>Active cancer</td>
<td>1</td>
<td></td>
<td>Pitting edema (greater in the symptomatic leg)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Heart rate 75-94 bpm</td>
<td>3</td>
<td>Collateral superficial veins (nonvaricose)</td>
<td>1</td>
<td></td>
<td>Past history of DVT</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Heart rate ≥95 bpm or more</td>
<td>5</td>
<td>Alternative diagnosis as likely or greater than that of DVT</td>
<td>-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The revised Geneva and Wells rules have recently been simplified and retrospective analysis suggests that these new models may be more effective, but prospective validation is required. Other prediction rules exist, but they have been largely replaced by the revised Geneva and Wells rules.
CTPA is contraindicated, such as in patients with chronic kidney disease or contrast allergies.

The widespread availability of CTPA and ultrasound, coupled with the potentially fatal nature of VTE, has resulted in a dramatic increase in the number of patients tested for PE and DVT, and therefore with a lower rate of positive tests but without a concomitant reduction in mortality. This is unfortunate because many studies in the past 15 years have proven that algorithm-based strategies enable rapid and safe exclusion of DVT or PE before diagnostic imaging. Although initially driven by the need to eliminate unnecessary invasive imaging and for patient convenience, the need to use these strategies is now of even greater importance due to overutilization of imaging tests.

**Diagnostic algorithms**

The ideal diagnostic strategy uses the benefits of clinical prediction rules and D-dimer and imaging tests in a stepwise approach. The first step is using a validated clinical prediction rule to determine pretest probability. If the prediction rule suggests a low, moderate, or unlikely probability of VTE, a negative VTE-validated D-dimer test rules out VTE and negates the need for diagnostic imaging. All other patients require imaging. Note that it is recommended that a negative D-dimer result should not be used to exclude VTE in patients who are high pretest probability because of the higher false negative rate in this subgroup.

Patients who require imaging for DVT can be managed with whole-leg ultrasound, in which a negative result rules out DVT, or by compression ultrasonography limited to the proximal venous system. With the latter approach, select patients require a repeat (serial) test 1 week later as outlined in Figure 1. Randomized trials have not demonstrated an advantage to the whole-leg approach, which will diagnose isolated calf vein DVT that may not require anticoagulant treatment. No study has used clinical probability in conjunction with whole-leg ultrasound, but data suggest a false negative rate of 2.5% in those at high probability for DVT.

The ideal strategy for diagnosing DVT in patients with a prior DVT in the symptomatic leg is still a subject of debate. Because ultrasound abnormalities may persist indefinitely with DVT, the criterion of vein compressibility may not distinguish patients with acute recurrent DVT from patients with chronic findings. It is helpful to recognize that acute DVT is usually occlusive, not echogenic, and it tends to be continuous. If the ultrasound reveals thrombosis that is echogenic, nonocclusive, or discontinuous, then chronic DVT should be considered. Comparison with previous ultrasound results may be helpful. Increase in clot diameter by 4 mm or evidence of new areas of thrombosis not previously seen on ultrasonography are strongly suggestive of recurrence.

It should be noted that clinical prediction rules for DVT and PE were developed and validated predominantly in outpatients and pregnant women were not evaluated in these studies. A prediction tool for DVT, yet to be validated, exists for pregnant women. Furthermore, the utility of the D-dimer test in hospitalized patients who often have other comorbidities (infection, postoperative) is lower because the D-dimer is rarely negative. Finally, if DVT is not a diagnostic possibility, a D-dimer test should not be done because positive results may redirect a clinician away from investigating the true cause of the leg symptoms toward unnecessary investigation for DVT.

For PE, the use of CTPA in combination with clinical assessment has a high positive and negative predictive value. Physicians can consider positive CTPA results as diagnostic if the pretest probability is high or the PE is located in a segmental vessel or larger, but not when the pretest clinical probability is low or unlikely or if the PE is located in the subsegmental arteries. In the latter cases, the results should be reviewed with a radiologist to consider a false-positive result because anticoagulation could potentially lead to more harm than benefit.

The appropriate use of V/Q in a validated diagnostic algorithm provides similar outcomes as multislice CTPA. CTPA produces fewer nondiagnostic test results than V/Q, but more auxiliary tests may be required to exclude false positives in patients diagnosed with subsegmental PE. A recent diagnostic study showed that managing patients with ultrasound and V/Q scanning avoids the need for CTPA in 89% of patients. Ultrasound may be used as the initial test in patients with suspected PE and complements the management of patients evaluated with V/Q scans or single-slice CTPA. Our suggested algorithm for the diagnosis of PE is illustrated in Figure 2.

Clinical assessment and D-dimer testing have the further advantage of enabling the management of patients presenting with suspected...
VTE at times when radiographic imaging is not routinely available. Patients in whom there is a moderate or high clinical suspicion of VTE may receive an injection of low-molecular-weight heparin (LMWH) in doses designed to treat acute VTE. Diagnostic imaging can then be arranged on an elective basis the following day. Because LMWH is a safe and effective therapy for patients with proven VTE, it also provides adequate protection for patients with suspected VTE. Patients at low risk by either clinical diagnostic models or with use of a sensitive D-dimer test may have diagnostic imaging delayed for a 12- to 24-hour period without the need for anticoagulant coverage.

Treatment

The goal of the therapy for VTE is to prevent the extension of thrombus, PE, and to relieve symptoms in the short term while preventing recurrent events in the long term. Extensive research evaluating the risk of recurrent VTE has established guidelines for the duration of anticoagulation, and this will be focus of another chapter in this publication. LMWH has changed the landscape of treatment DVT and PE by enabling home treatment and by providing an alternative long-term anticoagulant in those populations in whom warfarin is less effective, ineffective, or contraindicated. The following pertains to the treatment of PE and proximal lower extremity DVT, because there is little evidence to formulate recommendations for isolated calf DVT.

Initial therapy must involve therapeutic doses of either unfractionated heparin or LMWH, fondaparinux or rivaroxaban. Rivaroxaban and the new oral anticoagulants will be discussed by Dr Bauer in another chapter. Initial therapy with vitamin K antagonists (VKAs) alone is unacceptable. The ease of administration and efficacy of LMWH make this the preferred anticoagulant over IV or subcutaneous unfractionated heparin whether treatment is given as an outpatient or an inpatient. In a meta-analysis comparing the effectiveness of fixed-dose LMWH with adjusted-dose unfractionated heparin, significantly fewer deaths, major hemorrhaging, and recurrent VTE occurred with LMWH. Therefore, the current standard for initial treatment is to administer once-daily weight-adjusted LMWH until the international normalized ratio (INR) from the concomitant VKA therapy is therapeutic. This is generally 5 to 10 days. It remains unknown whether twice-daily dosing of LMWH is superior to once-daily dosing of LMWH. A meta-analysis suggested fewer hemorrhages and recurrences with twice-daily dosing, but the 95% confidence interval on the odds ratio crossed 1.0. Because LMWH is predominantly renally excreted, in patients with significant renal dysfunction, unfractionated heparin is the parenteral anticoagulant of choice.

Inpatient versus outpatient treatment

Early studies evaluating the outpatient treatment of DVT determined this practice to be safe and effective in most patients, with an improved quality of life and cost savings to the health care system. Outpatient treatment of PE is more controversial, although it has been the practice in many centers in Canada for more than 15 years and recent studies, including a randomized trial, may increase the comfort level for this strategy.

Long-term treatment of VTE

For the majority of patients with VTE, oral VKAs such as warfarin are very effective for the long-term prevention of recurrent thrombosis and, as will be discussed, the new oral anticoagulants can be also be used. The duration of long-term treatment varies depending on risk (the recent American College of Chest Physicians [ACCP] guidelines provides an excellent summary of this topic) and can be divided into 5 categories as follows.
(1) First VTE that occurs in the context of a transient risk factor (such as surgery or trauma) has a very low risk of recurrence and 3 months duration is adequate. (2) Patients with malignancy have a higher incidence of recurrent thrombosis and bleeding complications while receiving anticoagulation therapy. Long-term anticoagulation with LMWH instead of warfarin appears to be more effective at preventing recurrent venous thrombosis without a statistically significant increase in bleeding risk. It is our practice to treat all patients with active malignancy with at least 6 months of LMWH if there is adequate renal function. The use of LMWH rather than VKAs also facilitates the management of these complex patients who often undergo procedures (biopsy, line insertion, etc) and who have periodic thrombocytopenia due to chemotherapy. Because the risk of recurrence is high (3-fold higher in cancer vs noncancer patients), extended treatment with anticoagulation is recommended as long as the cancer is felt to be active and bleeding risk is not high (1B evidence from ACCP31). We generally wait 6 months after cure or complete remission before stopping therapy. (3) Recent data suggest that factor V Leiden, prothrombin gene mutation, protein C, protein S, antithrombin deficiency, and increased factor VIII levels do not sufficiently alter recurrence risk to be necessary for decisions about duration of therapy unless patients have combined or homozgyous genetic defects or very strong family history of VTE associated with the thrombophilic defect. Patients with persistently elevated antiphospholipid antibodies determined by either ELISA or clotting assays have a 2-fold higher relative risk of recurrence within 4 years after stopping anticoagulation and therefore are generally treated indefinitely.32 (4) After a second VTE, the risk of further thromboembolic events after the discontinuation of anticoagulation is felt to be excessive if only 6 months of oral anticoagulation is given. Therefore, we generally recommend continuing anticoagulation in this situation with yearly visits to assess bleeding risk, which enables a risk-benefit evaluation to determine whether anticoagulation should continue. If the bleeding risk is very high, then indefinite therapy may not be ideal. However, no study has looked at risk of recurrent VTE if both events occurred during a transient risk period. In this situation, a shorter duration of anticoagulation may be adequate (3-6 months), but other factors may influence this decision. (5) First VTE that occurs in the absence of temporary or identifiable ongoing risk factors for thrombosis (unprovoked) will be the topic of the chapter by Dr. Agnelli in this publication. Decisions on the need for indefinite therapy must be made because recurrence risk may be significant.

**Intensity of anticoagulation**

The standard intensity of oral anticoagulation with VKAs is determined by an INR of 2-3. In patients with antiphospholipid antibody-related thrombosis, it has long been felt that higher intensity anticoagulation is needed to prevent recurrence, but randomized controlled trials found that standard anticoagulation is as effective as high-intensity treatment even in this subgroup of patients.33 Therefore, high-intensity anticoagulation is not recommended in any patient with VTE. Maintaining good INR control will decrease the risk of developing post-phlebitic syndrome. There has also been debate on the usefulness of a reduced intensity regimen of anticoagulation (INR 1.5-1.9) long-term to prevent recurrent thrombosis while reducing the risk of bleeding. A large randomized trial has shown that low-intensity anticoagulation is less effective at preventing recurrent thrombosis and does not lead to a lower risk of bleeding.34 Therefore, low-intensity therapy is not recommended, but is more effective than no therapy.35

**Upper extremity DVT**

Upper extremity DVT (UEDVT) can be subdivided into catheter-related and non-catheter-related thrombosis. There is a risk of PE with this condition, so treatment with anticoagulation is generally recommended. Thrombolytic therapy as initial therapy for acute UEDVT has been used with some success, but no randomized controlled trials comparing thrombolytic therapy with anticoagulation alone have been performed. A more detailed discussion of UEDVT is beyond the scope of this article, and we refer the reader to a review addressing this topic.31

**Pregnancy**

The treatment of VTE during pregnancy deserves special mention because treatment with oral anticoagulation is generally avoided during pregnancy due to the teratogenic effects in the first trimester and the risks of fetal intracranial bleeding in the third trimester. LMWH is the treatment of choice for VTE during pregnancy. However, there is no consensus as to what the appropriate dose should be and whether anti-Xa levels need to be monitored. If acute DVT occurs near term, interrupting anticoagulation may be hazardous because of the risk of PE, and a temporary inferior vena cava filter must be considered. This topic was well reviewed recently.36,37

**Other interventions for VTE Treatment**

Although anticoagulation is the mainstay of treatment of DVT, thrombolysis and inferior vena cava filters are 2 interventions that deserve mention. The addition of systemic thrombolysis to standard anticoagulation leads to earlier patency of an occluded vein, but does not affect the rate of PE. There is a definite increase in major hemorrhage, including intracranial hemorrhage, with thrombolitics. Catheter-directed thrombolysis has also been reported to increase bleeding complications. It is unclear whether the earlier recanalization seen with thrombolytics translates into lower rates of postthrombotic syndrome long term. Thrombolysis for DVT is not generally recommended except in the case of massive DVT leading to phlegmasia cerulea dolens and threatened limb loss. The role of catheter-directed thrombolysis and clot desiccation is being evaluated in the ongoing ATTRACT randomized controlled trial, which should provide further guidance about its role for patients with proximal DVT.

Systemic administration of thrombolysis for PE has now been the subject of 2 well performed randomized trials (one pending publication), but it does not appear to result in a mortality reduction and due to higher risk of significant hemorrhage should likely be reserved for those with hemodynamic compromise or deterioration on standard anticoagulant therapy.38

Inferior vena cava filter placement in addition to anticoagulation has not been found to prolong survival in patients with DVT. Although it prevents PE, the insertion of a filter increases the risk of recurrent DVT.39 A retrievable filter is indicated when there is a contraindication to anticoagulation therapy (recent hemorrhage, impending surgery) in patients with newly diagnosed proximal DVT. It remains to be determined whether a retrievable filter in patients at higher risk of death (eg, those with limited cardiopulmonary reserve) will lead to a reduction in PE-related mortality.

Post-phlebitic syndrome is a frequent complication of DVT that has received relatively little attention. It is a major public health issue and an under-researched area. It is unclear who is at highest risk and how best to prevent and treat this complication. Some data suggest a
potential benefit from the use of graduated compression stockings to prevent this complication after DVT, but findings from a recent randomized placebo-controlled trial suggest otherwise.\textsuperscript{50}

Disclosures
Conflict-of-interest disclosure: P.W. has received honoraria from BMS, Pfizer, Bayer, and Boehringer Ingelheim. D.A. is on the board of directors or an advisory committee for, has received research funding from, has consulted for, and has been affiliated with the speakers’ bureaus for Bayer Pharma, Pfizer Pharmaceuticals, and Boehringer Ingelheim. Off-label drug use: None disclosed.

Correspondence
Philip Wells, Suite M1857, 501 Smyth Road, Ottawa Hospital, General Campus, Ottawa, ON K1H 8L8, Canada; Phone: 613-737-8755; Fax: 613-737-8851; e-mail: pwells@toh.on.ca.

References